Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs
Travera Inc
Travera Inc
Beijing Kejing Biotechnology Co., Ltd.
Eastern Cooperative Oncology Group
NKGen Biotech, Inc.
National Cancer Institute (NCI)
M.D. Anderson Cancer Center